BioHarvest Sciences Inc.

Recent News

  • BioHarvest Sciences Inc. Appoints Dr. George Garibaldi to Its Scientific Board of Advisors

    Dr. Garibaldi's 40 years of experience brings industry-leading pharmaceuticals development expertise to the Scientific Board of Advisors.His appointment demonstrates the company's resolve to leverage its biotechnology platform for enabling drugs development.Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - January 17, 2023) - BioHarvest Sciences Inc. (CSE: BHSC) ("BioHarvest" or the "company") announces that effective immediately, Dr. George Garibaldi will serve on its Scientific Board of Advisors. Complementing a top-tier group that includes a significant array of expertise, Dr. Garibaldi brings...

    2023-01-17 7:30 AM EST
  • BioHarvest Sciences Inc. Announces Live Quarterly Shareholder Update Event January 19, 2023, at 2:00 PM E.T.

    Vancouver, British Columbia, and Rehovot, Israel--(Newsfile Corp. - January 11, 2023) - BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB:CNVCF) ("BioHarvest" or "the Company") invites its shareholders and the general public to join a Live Video Conference ("Webinar") on Thursday, January 19, 2023, at 2:00 PM Eastern Standard Time (11:00 AM Pacific Standard Time).BioHarvest Sciences CEO Ilan Sobel will host this first shareholder event of 2023, and will present the Q4 2022 VINIA®  sales results, provide an update on Cannabis commercialization, and...

    2023-01-11 8:00 AM EST
  • Bioharvest Sciences Inc. 2022 CEO Letter to Shareholder Partners

    Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - December 29, 2022) - BioHarvest Sciences Inc.("BioHarvest" or the "Company") (CSE: BHSC) (OTCQB: CNVCF) is pleased to provide the following year-end shareholder partner letter from CEO Ilan Sobel.Dear Shareholder Partner,What a year 2022 was for BioHarvest! We made big steps in our journey to build a multi-billion-dollar biotech company with a clear vision of bringing millions of consumers the next generation of science-based therapeutic solutions. 2022 saw us build foundational capabilities which...

    2022-12-29 8:30 AM EST
  • BioHarvest Sciences Inc. Projects 2023 Revenue to Grow 3.0X-3.5X to a Range of USD $17M-$20M

    Cash flow break-even projected for Q4 2023Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - December 15, 2022) -  BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) ("BioHarvest" or "the Company") is estimating 2023 revenue to be between USD $17M-20M, representing a significant growth of at least 3X over 2022. Revenue for 2022 is now estimated to be USD $5.5M-$5.7M, meeting the guidance range provided by the company in Q1 of this year.The Company is also projecting to achieve cash flow break-even in Q4...

    2022-12-15 7:00 AM EST
  • Royal Emerald Pharmaceuticals Partners with BioHarvest Sciences to Supply Disruptive Cannabis Solutions to Companies Conducting FDA-Approved Medical Research

    Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 16, 2022) -  BioHarvest Sciences (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV), a leading biotech company focused on plant bio-cells growth for the nutraceutical and the medicinal cannabis markets, today announced the signing of a binding Letter of Intent (LOI) with Royal Emerald Pharmaceuticals (REP), one of only seven Drug Enforcement Administration (DEA) bulk manufacturing registration holders permitted to grow marijuana in the United States for drug related studies approved by the...

    2022-11-16 7:44 AM EST
  • BioHarvest Sciences Inc. Announces Closing of the Second Tranche of Private Placement of Convertible Notes and Expects the Offering to Be Oversubscribed and to Close an Additional Tranche of up to $3 Million by December 15, 2022

    This press release does not constitute an offer to sell or a solicitation to buy any securities in any jurisdiction.Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 15, 2022) - BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) ("BioHarvest" or the "Company") is pleased to announce that it has closed the second tranche (the "Second Tranche") of its non-brokered private placement of convertible notes (the "Notes") previously announced on October 7, 2022. Due to the significant demand for this...

    2022-11-15 1:56 PM EST
  • BioHarvest Sciences CEO to Detail Multi-Pronged Cannabis Strategy in North America at Online Webinar, Nov 16 at 2pm ET

    Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 14, 2022) - BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) ("BioHarvest" or "the Company") announces that CEO Ilan Sobel will host an online investor presentation on Wednesday, November 16. Following the October 25th breakthrough achievement and other important recent developments at BHSC and in the Cannabis market, the Company invites all interested investors and media to register for this event, where Ilan Sobel will share updated details on the...

    2022-11-14 1:59 PM EST
  • BioHarvest Introduces its 1st Cannabis Breakthrough Composition with Major Medical and Commercial Implications

    BioHarvest demonstrates unprecedented Cannabinoids tuning and elicitation capabilities (12X increase versus original plant) using its proprietary Bio-Plant CELLicitation™ platform technologyContains high amounts of minor Cannabinoids such as THCV (2.5%) and CBDV (4.4%) providing unique medical and commercial benefitsThe Company plans to reveal additional information related to its high THC Cannabis product line by year end Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - October 25, 2022) - BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) ("BioHarvest" or "the Company")...

    2022-10-25 8:05 AM EDT